Journal of the American Society of Nephrology : JASN
-
J. Am. Soc. Nephrol. · Nov 2020
Randomized Controlled Trial Multicenter StudyA Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
Hyperphosphatemia is associated with increased fibroblast growth factor 23 (FGF23), arterial calcification, and cardiovascular mortality. Effects of phosphate-lowering medication on vascular calcification and arterial stiffness in CKD remain uncertain. ⋯ Australian Clinical Trials Registry, ACTRN12610000650099.